depatuxizumab mafodotin

a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead

Also Known As:

ABBV-221; L-Valinamide, N-(6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1S,2R)-3-(((1S)-1-carboxy-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidi nyl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl; N-(6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl)-N-methyl-L-valyl-N-((3R,4S,5S)-1-((2S)-2-((1S,2R)-3-(((1S)-1-carboxy-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-3-methoxy-5-methyl-1-oxo-4-heptanyl)-N-methyl-L-valinamide; depatux-m

Networked: 28 relevant articles (8 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gan, Hui K: 7 articles (01/2021 - 12/2017)
2.	Scott, Andrew M: 7 articles (01/2021 - 12/2017)
3.	Xiong, Hao: 5 articles (12/2021 - 12/2017)
4.	Eoli, Marica: 5 articles (08/2021 - 01/2020)
5.	Reilly, Edward B: 5 articles (04/2021 - 01/2018)
6.	Franceschi, Enrico: 4 articles (08/2021 - 01/2020)
7.	Golfinopoulos, Vassilis: 4 articles (08/2021 - 01/2020)
8.	Gorlia, Thierry: 4 articles (08/2021 - 01/2020)
9.	Looman, Jim: 4 articles (08/2021 - 01/2020)
10.	Weller, Michael: 4 articles (08/2021 - 01/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "This phase 1/2 study evaluated the safety, pharmacokinetics, and efficacy of depatux-m in patients who had advanced solid tumors with known wild-type EGFR overexpression, amplification, or mutated EGFR variant III. A 3 + 3 dose escalation was used, and 2 dosing schedules were evaluated. " 12/01/2021 - "Poor efficacy in orthotopic PDXs was associated with limited and heterogeneous distribution of Depatux-M into tumor tissues, and artificial disruption of the BBB or bypass of the BBB by direct intracranial injection of Depatux-M into orthotopic tumors markedly enhanced the efficacy of drug treatment. " 01/01/2021 - "Both preclinical and clinical data showed intra-tumoral concentration and efficacy of Depatux-m inversely correlated with tumor size. " 12/01/2021 - "In contrast to the profound benefit observed in heterotopic tumors, only two of seven intrinsically sensitive PDXs were responsive to Depatux-M as intracranial tumors. " 01/01/2018 - "Based on these results, ABBV-221 has advanced to a phase I clinical trial in patients with advanced solid tumors associated with elevated levels of EGFR. "
2.	Glioblastoma (Glioblastoma Multiforme) 12/01/2017 - "Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study." 01/01/2023 - "However, depatuxizumab mafodotin, an ADC targeting wild-type EGFR and EGFR variant III, did not provide a definitive overall survival benefit in patients with newly diagnosed or recurrent EGFR-amplified glioblastoma in phase II and III trials, despite objective radiological responses in some patients. " 01/01/2021 - "Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma." 01/01/2018 - "Depatux-m has demonstrated promising clinical activity in glioblastoma multiforme (GBM) patients and is currently being evaluated in clinical trials in first-line and recurrent GBM disease settings. " 01/01/2023 - "Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial."
3.	Glioma (Gliomas) 12/01/2021 - "Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial." 12/01/2021 - "In first-line arms, patients with newly diagnosed WHO grade III/IV glioma received Depatux-M plus chemoradiotherapy. " 12/01/2021 - "This study showed acceptable safety profile of Depatux-M alone or plus chemotherapy/chemoradiotherapy in Japanese patients with WHO grade III/IV glioma. " 01/01/2020 - "Depatux-M and temozolomide in advanced high-grade glioma." 12/01/2021 - "In second-line arms, patients with EGFR-amplified recurrent WHO grade III/IV glioma received Depatux-M plus chemotherapy (temozolomide) or Depatux-M alone regardless of EGFR status. "
4.	Hypersensitivity (Allergy) 01/01/2020 - "Ligand hypersensitivity can explain the therapeutic efficacy of depatux-m as increased ligand-induced activation will result in increased exposure of the epitope to the antibody-drug conjugate. "
5.	Gliosarcoma 05/31/2023 - "The study enrolled adult patients with epidermal growth factor receptor-amplified, histologically confirmed, newly diagnosed supratentorial glioblastoma or grade IV gliosarcoma, and a Karnofsky Performance Status ≥70, receiving depatuxizumab mafodotin. "

Related Drugs and Biologics

1.	depatuxizumab mafodotin
2.	Temozolomide (Temodar)
3.	Immunoconjugates (Immunoconjugate)
4.	Epitopes
5.	Nucleotides
6.	Ligands
7.	ErbB Receptors (EGF Receptor)
8.	Lomustine (CCNU)
9.	Zirconium-89
10.	monomethylauristatin F

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Chemoradiotherapy